TY - JOUR
T1 - The role of laser wavelength in the treatment of vitreoretinal diseases
AU - Dyer, D. S.
AU - Bressler, S. B.
AU - Bressler, N. M.
PY - 1994/1/1
Y1 - 1994/1/1
N2 - Advances in laser technology have provided ophthalmologists with lasers spanning the visible and near-infrared spectrum. Recently, prospective, randomized clinical trails have compared laser wave-lengths in the treatment of specific disorders. The Krypton Argon Regression Neovascularization Study found no difference between argon blue-green and krypton red laser when performing panretinal photocoagulation to manage proliferative diabetic retinopathy. The Macular Photocoagulation Study Group and the Canadian Ophthalmology Study Group have independently found no substantial difference in treatment outcome when using argon green versus krypton red laser to treat choroidal neovascularization in eyes with age-related macular degeneration. These recent trials and others that evaluate laser management of proliferative diabetic retinopathy, choroidal neovascularization, retinopathy, of prematurity, and retinal breaks are reviewed. Multiple studies have failed to identify a moderate difference in treatment outcome between treatments performed with different laser wavelengths; however, small differences in outcome cannot be excluded without further study involving great numbers of patients. At the present time, ophthalmologists should be reassured that individual preferences for one wavelength over another in specific situations should not have a major effect on the visual outcome of the procedure.
AB - Advances in laser technology have provided ophthalmologists with lasers spanning the visible and near-infrared spectrum. Recently, prospective, randomized clinical trails have compared laser wave-lengths in the treatment of specific disorders. The Krypton Argon Regression Neovascularization Study found no difference between argon blue-green and krypton red laser when performing panretinal photocoagulation to manage proliferative diabetic retinopathy. The Macular Photocoagulation Study Group and the Canadian Ophthalmology Study Group have independently found no substantial difference in treatment outcome when using argon green versus krypton red laser to treat choroidal neovascularization in eyes with age-related macular degeneration. These recent trials and others that evaluate laser management of proliferative diabetic retinopathy, choroidal neovascularization, retinopathy, of prematurity, and retinal breaks are reviewed. Multiple studies have failed to identify a moderate difference in treatment outcome between treatments performed with different laser wavelengths; however, small differences in outcome cannot be excluded without further study involving great numbers of patients. At the present time, ophthalmologists should be reassured that individual preferences for one wavelength over another in specific situations should not have a major effect on the visual outcome of the procedure.
UR - http://www.scopus.com/inward/record.url?scp=0028272167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028272167&partnerID=8YFLogxK
U2 - 10.1097/00055735-199406000-00007
DO - 10.1097/00055735-199406000-00007
M3 - Review article
C2 - 10147457
AN - SCOPUS:0028272167
VL - 5
SP - 35
EP - 43
JO - Current Opinion in Ophthalmology
JF - Current Opinion in Ophthalmology
SN - 1040-8738
IS - 3
ER -